Edition:
United Kingdom

Aerpio Pharmaceuticals Inc (ARPO.OQ)

ARPO.OQ on NASDAQ Stock Exchange Capital Market

0.99USD
22 Apr 2019
Change (% chg)

-- (--)
Prev Close
$0.99
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
101,723
52-wk High
$4.35
52-wk Low
$0.88

Latest Key Developments (Source: Significant Developments)

Aerpio Pharma Says Board Approved Plan To Reduce Operating Costs, Align Workforce
Thursday, 4 Apr 2019 

April 4 (Reuters) - Aerpio Pharmaceuticals Inc ::AERPIO PHARMACEUTICALS SAYS ON APRIL 1,BOARD APPROVED A REALIGNMENT PLAN TO REDUCE OPERATING COSTS AND ALIGN ITS WORKFORCE - SEC FILING.AERPIO PHARMACEUTICALS INC - REALIGNMENT PLAN REDUCES ITS CURRENT WORKFORCE BY 11 EMPLOYEES, REPRESENTING APPROXIMATELY 41% OF COMPANY'S WORKFORCE.AERPIO PHARMACEUTICALS INC - ACTION IS EXPECTED TO BE SUBSTANTIALLY COMPLETE BY APRIL 30, 2019.AERPIO PHARMACEUTICALS - DUE TO REALIGNMENT PLAN, CO ESTIMATES IT WILL INCUR ONE-TIME AGGREGATE EXPENSES OF ABOUT $0.9 MILLION FOR EMPLOYEE RELATED COSTS.AERPIO PHARMACEUTICALS INC - COMPANY ANTICIPATES THAT MAJORITY OF SUCH EMPLOYEE RELATED COSTS WILL BE PAID DURING SECOND AND THIRD QUARTERS OF 2019.  Full Article

Aerpio Pharmaceuticals Announces Results From TIME-2B Study Of AKB-9778 In Diabetic Retinopathy
Monday, 18 Mar 2019 

March 18 (Reuters) - Aerpio Pharmaceuticals Inc ::AERPIO PHARMACEUTICALS ANNOUNCES RESULTS FROM TIME-2B STUDY OF AKB-9778 IN DIABETIC RETINOPATHY.AERPIO PHARMACEUTICALS INC - TIME-2B STUDY DID NOT MEET PRIMARY ENDPOINT OF 2-STEP REDUCTION IN DRSS SCORE.AERPIO PHARMACEUTICALS INC - AKB-9778 DID SHOW ENCOURAGING DATA IN A NUMBER OF PRESPECIFIED, KEY SECONDARY ENDPOINTS.AERPIO PHARMACEUTICALS INC - AKB-9778 WAS FOUND TO BE SAFE AND WELL-TOLERATED.AERPIO PHARMACEUTICALS INC - IN RESULTS, THERE WAS ONE DEATH IN STUDY, AND IT WAS IN PLACEBO GROUP..AERPIO PHARMACEUTICALS - EXPECTS TO INITIATE A PHASE 1B STUDY IN Q2 OF 2019 WITH RESULTS ANTICIPATED BY END OF 2019.  Full Article

Aerpio Reports Q4 Loss Per Share $0.21
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Aerpio Pharmaceuticals Inc ::AERPIO REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.21.Q4 EARNINGS PER SHARE ESTIMATE $-0.23 -- REFINITIV IBES DATA.AS OF DECEMBER 31, 2018, CASH AND CASH EQUIVALENTS TOTALED $62.6 MILLION..  Full Article

Aerpio Pharmaceuticals Reports Q3 EPS of $0.28
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Aerpio Pharmaceuticals Inc ::AERPIO REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 EARNINGS PER SHARE $0.28.Q3 REVENUE $18.8 MILLION VERSUS I/B/E/S VIEW $18.7 MILLION.Q3 EARNINGS PER SHARE VIEW $0.29 -- THOMSON REUTERS I/B/E/S.  Full Article

Aerpio Reports Q2 loss per share $0.22
Tuesday, 14 Aug 2018 

Aug 14 (Reuters) - Aerpio Pharmaceuticals Inc ::AERPIO REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.22.AERPIO PHARMACEUTICALS - AS OF JUNE 30 CASH AND CASH EQUIVALENTS TOTALED $68.8 MILLION, COMPARED TO $20.3 MILLION AS OF DEC 31, 2017..  Full Article

Aerpio Pharma Announces Proposed Public Offering Of Common Stock
Monday, 25 Jun 2018 

June 25 (Reuters) - Aerpio Pharmaceuticals Inc ::AERPIO PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND UPLISTING TO NASDAQ CAPITAL MARKET.AERPIO PHARMACEUTICALS - INTENDS TO SELL $40 MILLION OF ITS COMMON STOCK IN UNDERWRITTEN PUBLIC OFFERING.  Full Article